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Objective: To investigate maternal thrombophilia in cases of Stillbirth (SB), also an uncertain topic because
most case series were not characterised for cause/associated conditions of death.
Study design: In a consecutive, prospective, multicentre design, maternal DNA was obtained in 171 cases of
antenatal SB and 326 controls (uneventful pregnancy at term, 1:2 ratio). Diagnostic work-up of SB included
obstetric history, neonatologist inspection, placenta histology, autopsy, microbiology/chromosome evalua-
tions. Results audited in each centre were classiﬁed by two of us by using CoDAC. Cases were subdivided
into explained SB where a cause of death was identiﬁed and although no deﬁned cause was detected in
the remnants, 64 cases found conditions associated with placenta-vascular disorders (including preeclamp-
sia, growth restriction and placenta abruption — PVD). In the remnant 79 cases, no cause of death or associ-
ated condition was found.
Antithrombin activity, Factor V Leiden, G20210A Prothrombin mutation (FII mutation) and acquired throm-
bophilia were analysed.
Results: Overall, the presence of a thrombophilic defect was signiﬁcantly more prevalent in mothers with SBs
compared to controls. In particular, SB mothers showed an increased risk of carrying Factor II mutation
(OR=3.2, 95% CI: 1.3–8.3, p=0.01), namely in unexplained cases. Such mutation was signiﬁcantly associat-
ed also with previous SB (OR=8.9, 95%CI 1.2–70.5). At multiple logistic regression, Factor II mutation was
the only signiﬁcantly associated variable with SB (adj OR=3.8, 95% CI: 1.3–13.5).
Conclusion: These data suggest that Factor II mutation is the only condition speciﬁcally associated with unex-
plained SB and could represents a risk of recurrence. PVD-associated condition is unrelated to thrombophilia.
© 2011 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Thrombophilia (i.e., congenital mutation of coagulation factors V
and II, reduction of anticoagulatory protein or the presence of lupus
anticoagulant/phospholipid antibodies) has been proposed to be re-
lated to adverse pregnancy outcomes. Considering that inherited
thrombophilia is a predisposition to a hypercoagulation state with
formation of thrombi, researchers have focussed their attention onda Ospedaliero Universitaria,
22512.
Ltd. All rights reserved.pregnancy complications related to circulatory disorders. Studies per-
formed in women having preeclampsia (PE), foetal growth restriction
(FGR), placenta abruption and foetal demise gave conﬂicting data,
mainly because of differences in population features and clinical def-
initions [1–3]. However, the combination of adverse obstetric out-
comes with the presence of antiphospholipid antibodies has been
recognised as a separate syndrome, termed antiphospholipid syn-
drome, and it represents the most common acquired thrombophilia
[4].
The issue of foetal demise or stillbirth (SB) is further complicated
by poor knowledge and low interest in the subject, which has been
addressed only in recent years [5]. The main problem in comparing
available data has been the absence of a uniform deﬁnition amongst
different countries [6].
Table 1
Classiﬁcation of stillborn according to CoDAC.





Cause of death Code n Associated condition Code n n
Malformations 300 7















671 1 Severe gestational
hypertension
712 4
Total number 29 63 79
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several studies [7–9], a deﬁnite cause of foetal death in utero could be
ascertained in less than one third of the cases, thus complicating com-
munication with parents and management of the next pregnancy
[10]. Accordingly, it has not been determined whether thrombophilia
should be considered a risk factor for SB [11,12].
In a comprehensive view, SB should be interpreted as an interac-
tion of foetal conditions, maternal environment and circumstances.
Maternal thrombophilia could be one of many negative maternal pre-
disposing factors. Unfortunately, in the clinical series published thus
far, the described confounding factors have seldom been taken into
account.
Therefore, this case–control study evaluated the association be-
tween thrombophilia and SB according to maternal and foetal condi-
tions known to be involved in foetal death.
2. Materials and methods
2.1. Subjects
This population-based study was part of a comprehensive national
programme to investigate the epidemiology, risk factors, causes and
management of SB and was sponsored by the Italian Ministry of Edu-
cation, University and Research. Recruitment occurred from June
2005 to June 2007 in the maternal–foetal medicine units of 9 univer-
sity hospitals in northern and central Italy. The Ethics Committee ap-
proved the study, including collection and storage of blood for
extracting DNA. Sensitive information was treated according to the
Italian “Privacy Act”.
Cases were categorised as stillborn when neonates at ≥22 weeks
of gestation or N500 g (if gestational ultrasound age was not avail-
able) had Apgar scores of 0 for the 1st and 5th minutes and were
not actively resuscitated. Consecutive antepartum SB cases were in-
cluded, and intrapartum cases were excluded. Ninety-one percent of
the pregnancies were dated by a ﬁrst trimester ultrasound; the foetal
weight criterion was utilised in only 2 cases.
Controls, deﬁned as women having an uneventful pregnancy at
term, were randomly enrolled amongst women delivering at the
same hospitals. The women were recruited in a 2:1 ratio for each
case and matched for age (±2 years) and ethnicity.
Socio-demographic variables, maternal and obstetric history,
pregnancy course, circumstances of SB and parturition were already
on ﬁle. Data were collected through an ad hoc electronic form.
To classify the causes of death, the same work-up protocol was
adopted by participant centres, which included careful obstetric his-
tory and circumstances of SB diagnosis collected in an ad hoc form at-
tached to maternal diary, placenta histology, stillborn autopsy,
microbiology evaluation (cultures of neonatal blood and placenta
swab; superﬁcial swabs from neonate), chromosome analysis (from
either amniotic ﬂuid or blood, or fascia lata) and neonate inspection.
As expected, cytogenetic cultures failed in 40% of cases; autopsy and
placenta histology was available in N95% of subjects. Causes of
death and/or signiﬁcant associated circumstances were recorded
and audited at each participating centre. Then, the data were
reviewed by an obstetrician (FF) and neonatologist (GG), which
used up-to-date CoDAC classiﬁcation [13]. Discrepancies were dis-
cussed and solved by consensus.
Thus, SBs have been subdivided into three groups. Cases where a
cause of death was recognised (excluding those with placenta involve-
ment) were grouped as EXPLAINED, (Table 1). Clinical disorders be-
longing to abnormal vascular/placenta function were grouped as PVD
and include small for gestational age newborns (birthweightb10th
percentile according to gestational age and sex), preeclampsia and se-
vere hypertension according to the American College of Obstetricians
and Gynecologists [14], and placenta abruption. Finally, cases without
a deﬁned cause of death were grouped as UNEXPLAINED.2.2. Methods
Antithrombin activity (AT) was routinely evaluated in all patients
at admission. Eight to 12 weeks after delivery, blood was drawn from
the women for DNA analysis to look at factor V Leiden and factor II
G20210A mutations and assess anticardiolipin antibodies and lupus
anticoagulants. The assessment for acquired thrombophilia was re-
peated 6–12 weeks later. The molecular diagnosis of factor V Leiden
was performed according to Bertina et al. [15]. The prothrombin
gene mutation was detected using a slight modiﬁcation of the Poort et
al. method [16]. The concentrations of IgG/IgM anticardiolipin antibodies
were determined by speciﬁc ELISA (cut-off values, IgG _21 GPL/mL and
IgM _21 MPL/mL). The presence of lupus anticoagulant was determined
as previously described [17]. The presence of anticardiolipin antibodies
and/or lupus anticoagulant was grouped as acquired thrombophilia.
Statistical analysis was performed with SPSS 17 software using the
Chi-square test, analysis of variance, and logistic regression. To calculate
the study power, we used thrombophilia prevalence data reported in
Italian women with uneventful pregnancies [18,19]. According to Mar-
tinelli et al. [19], we hypothesised a three-fold prevalence in cases with
SB. Hence, with a power of 0.80, 150 cases and 300 controls would be
sufﬁcient to detect a signiﬁcant difference (pb0.05) between groups.
3. Results
Out of 239 eligible women, maternal thrombophilia was investi-
gated in 171 consecutive cases. Although thrombophilia was advice
amongst exams pertinent to SB evaluation, one centre disagree and
some of the remnants started to collect data later.
Cause of death and associated condition are detailed in Table 1.
Cases and controls were homogeneous with respect to age, parity,
education, and ethnicity. BMIN25 was found signiﬁcantly more repre-
sented in cases respect with controls (Table 2). Additional clinical fea-
tures of the 3 subgroups of SB are reported in Table 3. Age, BMI and
ethnicity were equally distributed amongst groups. Stillbirth at term
was signiﬁcantly more prevalent in the UNEXPLAINED subgroup
(OR=5.04, 95% CI: 2.24–11.50), whereas the presence of a previous
SB was reported slightly more in the PVD subgroup.
Overall, the presence of a thrombophilic defect was signiﬁcantly
more prevalent in mothers with SBs compared to mothers with un-
eventful full-term pregnancies (Table 4). Factor V Leiden frequencies
and acquired thrombophilia were similar in cases and controls whilst
SB mothers showed an increased risk of carrying Factor II mutation
(OR=3.2, 95% CI: 1.3–8.3, p=0.01). In both cases and controls, Fac-
tor V Leiden and Factor II mutation were heterozygous. No cases of
homozygous mutations were detected.
Table 2
Clinical features of the mothers in cases and controls. Data are reported as N with % in
brackets.
Stillborn n=171 Controls n=326
Age
≤25 years 18/171 (10.5) 40/287 (13.9)
26–34 years 89/171 (52) 151/287 (52.6)
≥35 years 64/171 (37.4) 96/287 (33.4)
Ethnicity
Caucasian 124/171 (72.5) 233/326 (71.5)
Non Caucasian 47/171 (27.5) 93/326 (28.5)
Nulliparity
80/171 (46.8) 166/315 (52.7)
Previous stillbirth
11/170 (6.5) 10/322 (3.1)
Education
≤8 years 34/121 (28.1) 60/278 (21.6)
N8 years 87/121 (71.9) 218/278 (78.4)
Pre-pregnancy BMI⁎
b20 13/149 (8.7) 24/295 (8.1)
21–25 77/149 (51.7) 189/295 (64.1)
26–30 41/149 (27.5) 64/295 (21.7)
N30.1 18/149 (12.1) 18/295 (6.1)
⁎ p=0.039.
Table. 4
Prevalence of maternal thrombophilic factors in stillborn and controls. Number of cases
with % reported in brackets.
Stillborn Controls OR
FV Leiden 9/167 (5.4) 8/318 (2.5) 2.2 (0.8–6.4)
FII mutation 14/164 (8.5) 9/319 (2.8) 3.2 (1.3–8.3)
Acquired thrombophilia 10/171 (5.8) 11/326 (3.4) 1.8 (0.7–4.6)
Any thrombophilia 33/171 (19.2) 28/334 (8.4) 2.8 (1.6–5.0)
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Factor II mutation was the only signiﬁcant variable associated with
unexplained SB (p=0.007). As a whole, inherited thrombophilia (Fac-
tor II+Factor V Leiden)was represented equally in EXPLAINED (14.3%),
PVD (11.7%) and UNEXPLAINED (15.2%) subgroups. The UNEXPLAINED
SB subgrouphad a risk of 3.2 (95% CI: 1.3–7.4; p=0.005) for carrying an
inherited thrombophilia defect.
AT was normal in every subject, and no AT deﬁciencies were
found.
The presence of thrombophilia has been correlated with several
confounding factors, including ethnic group, previous SB, BMI, gesta-
tional age at death, preeclampsia, and HELLP Syndrome and FGR. The
obstetric history demonstrated that 11/88 pluriparas (12.5%) had a
prior SB. Factor II mutation was signiﬁcantly associated with a posi-
tive history for SB (OR=8.9, 95% CI: 1.2–70.5). The remnant variables
were not signiﬁcantly correlated with either inherited or acquired
thrombophilia.Table 3
Clinical features of the mothers in 3 subgroups of SB. Data are reported as N with % in
brackets. Gestational age and the rate of previous stillbirth are signiﬁcantly different
among subgroups.
Explained n=29 PVD n=63 Unexplained n=79
Age
≤25 years 3 (10.3) 9 (14.3) 8 (10.1)
26–34 years 12 (41.4) 36 (57.1) 42 (53.1)
≥35 years 14 (48.3) 18 (28.6) 29 (36.8)
Ethnicity
Caucasian 24 (82.7) 50 (79.4) 65 (82.3)
Asian 2 (6.9) 7 (11.1) 6 (7.6)
Others 3 (10.4) 6 (9.5) 8 (10.1)
Nulliparity
9 (31) 31 (49.2) 43 (54.4)
Previous abortion (b20 weeks)
8 (27.6) 12 (19) 10 (12.6)
Previous stillbirth
1 (3.4) 7 (11.1) 3 (3.8)
Gestational age
b32 weeks 17 (58.6) 38 (60.3) 23 (29.1)
32+1–37 weeks 7 (24.1) 18 (28.6) 22 (27.8)
N 37+1 weeks 5 (17.3) 7 (11.1) 34 (43.1)
Pre-pregnancy BMI
b25 17 (58.6) 33 (52.4) 42 (53.1)
25.1–30 10 (34.5) 20 (31.7) 26 (32.9)
N30.1 2 (6.9) 10 (15.9) 11 (14)A multiple logistic regression was build-up. Dependent variable
was cases with SB. Independent confounding variables included in
the model were ethnicity, parity, BMI, previous SB, Factor V Leiden,
Factor II mutation and acquired thrombophilia. Factor II mutation
was the only signiﬁcantly associated variable (F=12.3, p=0.001),
explaining 3.9% of the variance. Factor II adjusted OR=3.8, 95% CI:
1.3–13.5.4. Discussion
As a whole, the data demonstrated that mothers presenting with
SBs have an increased risk of carrying thrombophilic defects. More
speciﬁcally, Factor II mutation is the single defect associated with
the occurrence of SB. The ﬁndings were derived primarily from the
ﬁgures representing the UNEXPLAINED subgroup.
Despite twometa-analyses [11,12], conclusions have been difﬁcult
to draw due to the heterogeneity of clinical samples, study design and
confounding factors. The most troubling issue has been the deﬁnition
of “unexplained SB”, which largely depends on the diagnostic work-
up performed in each one of the primary studies [13]. A strength of
this study is that enrolled cases have been thoroughly investigated
and audited, allowing classiﬁcation of causes and conditions associat-
ed with death, whereas this was reported only in a minority of previ-
ously published studies [19–23]. Recently, one study reported data
after categorisation of causes of death, including also paternal throm-
bophilia [24].
In light of our previous data, whether Factor V Leiden prevalence
in SB is increased with respect to uneventful pregnancies has
remained questionable. It seems likely that increasing sample size
also Factor V Leiden would reach statistical signiﬁcance in our cases
series. In any case, the reported odd risks have been quite low, rang-
ing 1.5 to 4.5 [19–24].Table 5
Prevalence of thrombophilia in the 3 subgroups of SB vs controls. Data are reported as
N and % in brackets. OR is reported with 95% Conﬁdence interval.
Explained SB versus controls
Explained Controls OR
FV Leiden 2/28 (7.1) 8/318 (2.5) 2.9 (0.2–16.4)
FII mutation 2/28 (7.1) 9/319 (2.5) 2.6 (0.2–14.2)
Acquired thrombophilia 0/29 (0) 11/326 (3.4) /
SB associated with placenta vascular disorders (PVD) versus controls
PVD Controls OR
FV Leiden 3/60 (5.0) 8/318 (2.5) 2.0 (0.2–8.8)
FII mutation 4/60 (6.7) 9/319 (2.5) 2.5 (0.6–9.2)
Acquired thrombophilia 3/63 (4.8) 11/326 (3.4) 1.4 (0.02–5.8)
Totally unexplained SB (Unexplained) versus controls
Unexplained Controls OR
FV Leiden 4/79 (5.1) 8/318 (2.5) 2.1 (0.5–7.8)
FII mutation 8/76 (10.5) 9/319 (2.5) 4.1 (1.4–12.0)a
Acquired thrombophilia 7/79 (8.9) 11/326 (3.4) 2.8 (0.9–8.1)
Total SB 172 (100) 326 (100) –
a Signiﬁcant association.
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represent a risk factor for SB. A prospective study by Said et al. [25]
has conﬁrmed this association despite few cases occurring in the co-
hort under study; this was expected from the SB prevalence, which
ranges 4–7/1000 in developed countries. Interestingly enough, we
also found that Factor II mutation is the only thrombophilic defect
presenting an association with a positive history of SB, perhaps indi-
cating an increased risk of recurrence.
These conclusions have been challenged by a study performed in
low-risk populations, which did not ﬁnd an association between factor
II mutation and pregnancy loss [23]. However, although the sample
size and appropriate prospective design measures were sufﬁcient, the
study included pregnancy loss as both ﬁrst trimester abortions and foe-
tal deaths occurring below the 20th week of gestation. Thus, conclu-
sions cannot directly apply to SB occurrence, which is deﬁned as
foetal death in utero with at least 20 weeks of gestational development.
The same limitation apply to the recent meta-analysis of Rodger et al.
[26].
In addition to SB, maternal thrombophilia has been associated
with several adverse pregnancy outcomes including severe pre-
eclampsia [18] and placenta abruption [27]; it is still debated whether
foetal growth restriction has to be linked to thrombophilia [28]. Also,
all of the above conditions were included amongst risk factors for SB
thereby complicating the picture [5–10]. Nevertheless, whilst clinical
evidence has suggested that placental dysfunction is correlated with
in utero demise, no histological [24–29] or functional [30] evidence
has supported thrombophilia as the linking pathogenetic mechanism.
Indeed, composite placenta-mediated pregnancy complications seem
not associated with Factor V Leiden [26]. Prothrombin gene mutation
ﬁgures however show a trend to be linked to the above described ad-
verse pregnancy outcomes.
A limitation of this study is that we used only term live-birth preg-
nancy as controls. This would have missed an association between
thrombophilias and adverse pregnancy outcomes resulting in pre-
term live-births. However, in most of the cases, case–control studies
were composed by uneventful pregnancies.
In conclusion, when SBs were deeply investigated and classiﬁed,
the association of foetal demise and maternal thrombophilia
appeared doubtful. Although this study suggested that prothrombin
gene mutation is a condition speciﬁcally associated with unexplained
intrauterine death, its impact seems low considering it explain a very
small proportion of the variance. However, prothrombin gene muta-
tion seems to represent a risk factor for recurrence [31]. In light of
multifactorial approaches and considering the relatively low associa-
tion strength, we should consider thrombophilia to be one amongst
other risk factors participating to SB occurrence.
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